BPX-201 Vaccine for Chemotherapy-Naïve mCRPC

Article

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve mCRPC.

Clinical Pearls

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology—Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

  • BPX-201 is novel, second-generation, autologous antigen presenting cell-based vaccine.
  • In a previous phase I trial, this has proven to be a potent approach to vaccination against prostate cancer.
  • There is hope that this approach will lead to both survival benefit and real-time benefit in the form of tumor responses and PSA reductions.
  • To date, 6 patients have been enrolled in the trial and no dose-limiting toxicities have been observed.

<<<

Back to "Immunotherapy News from ASCO"

Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content
Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024
Article

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Niraparib/Abiraterone/Prednisone Effective With Minimal AEs in BRCA+ mCRPC

Niraparib/Abiraterone/Prednisone Effective With Minimal AEs in BRCA+ mCRPC

April 8th 2024
Article

In an interview with Targeted Oncology, Kim N. Chi, MD, FRCPC, discussed the MAGNITUDE trial results, including patient-reported outcomes, in patients with BRCA-positive mCRPC.

Read More

A Deep Dive Into the Evolving Landscape of Prostate Cancer

A Deep Dive Into the Evolving Landscape of Prostate Cancer

January 15th 2024
Podcast

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Listen

New Strategies for Cervical Cancer Prevention With HPV Vaccines

New Strategies for Cervical Cancer Prevention With HPV Vaccines

March 31st 2024
Article

A quality initiative study investigated whether offering human papillomavirus vaccines at the time of abortion care could increase vaccination rates.

Read More

Evaluating Quality of Life Post HCT in Patients With AML

Evaluating Quality of Life Post HCT in Patients With AML

March 30th 2024
Article

Betty Hamilton, MD, discussed findings from a quality of life study in patients with FLT3 ITD-positive acute myeloid leukemia who underwent allogeneic stem cell transplant.

Read More